
On Wednesday, September 24, the share price of a little-known biotech company based in Amsterdam suddenly surged 247.7%.
The company, uniQure N.V. (QURE), saw its market cap surge to $2.76 billion after it announced positive trial results for its gene therapy treatment targeting Huntington's disease.